Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir

David L. Dunn, Jaime L. Mayoral, Kristen J. Gillingham, Cynthia M. Loeffler, Kenneth L. Brayman, Marie A. Kramer, Alejo Erice, Henry H. Balfour, Courtney V. Fletcher, R. Morton Bolman, Arthur J. Matas, William D. Payne, David E.R. Sutherland, John S. Najarian

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

The occurrence of cytomegalovirus infection after solid organ transplantation has been correlated with decreased patient and allograft survival. The disease has not been conquered for two major reasons: The length of time to establish the diagnosis of CMV has been excessive, and suitable, nontoxic antiviral agents have not been available for use. The purpose of this study was to examine the current incidence and impact of tissue-invasive cytomegalovirus (TI-CMV) disease that developed in 93 patients who underwent solid organ transplantation at University of Minnesota Hospitals (3/1/87 and 6/30/89) and who were treated with the antiviral agent ganciclovir ([9-(l, 3-dihydroxy-2-2-propoxymethyl)-guanine [DHPG]). During this same period of time 323 patients received kidney transplants and 71 received kidney-pancreas transplants. Three patient groups were defined: (1) no CMV; (2) CMV infection (cultural or serologic evidence of noninvasive CMV infection); and (3) evidence of TI-CMV disease based upon initial complaints of fever, malaise, dyspnea, or abdominal pain, leukopenia (WBC<3000/ml), and evidence of a positive CMV rapid antigen test, CMV culture, or the presence of characteristic CMV inclusion bodies upon examination of material obtained by means of bronchoscopy, upper-gastrointestinal endoscopy, colonoscopy, or liver or renal biopsy. Patients with solely fever, leukopenia, but without a rising CMV serum titer, or positive CMV urine or blood cultures were excluded from the study. A multivariate analysis revealed that rejection therapy, age >50 years, and receiving an organ from a seropositive donor were all significant variables that predisposed to TI-CMV. Analysis of patient and kidney allograft survival indicated that asymptomatic CMV infection had little current impact upon patient or allograft survival, while patients who developed TI-CMV exhibited higher rates of allograft loss and mortality, despite DHPG therapy. Comparison with historical group of patients indicated that TI-CMV DHPG-treated patients exhibited a trend toward improved allograft survival that may be relevant because the historical group of patients included patients with mild CMV in-fection. DHPG therapy was well tolerated and produced minimal toxicity, and excellent 30-day cure rates (89.2%), although 21.2% of patients required retreatment subsequently. We are currently conducting a trial to compare the ability of DHPG administered plus an anti-CMV immune globulin preparation with acyclovir to prevent posttransplant TI-CMV disease.

Original languageEnglish (US)
Pages (from-to)98-106
Number of pages9
JournalTransplantation
Volume51
Issue number1
DOIs
StatePublished - Jan 1991

Fingerprint

Ganciclovir
Cytomegalovirus
Transplants
Guanine
Allografts
Therapeutics
Organ Transplantation
Kidney
Antiviral Agents
Asymptomatic Infections
Retreatment
Acyclovir
Leukopenia
Cytomegalovirus Infections
Infection
Dyspnea
Abdominal Pain
Pancreas
Fever

ASJC Scopus subject areas

  • Transplantation

Cite this

Dunn, D. L., Mayoral, J. L., Gillingham, K. J., Loeffler, C. M., Brayman, K. L., Kramer, M. A., ... Najarian, J. S. (1991). Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir. Transplantation, 51(1), 98-106. https://doi.org/10.1097/00007890-199101000-00015

Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir. / Dunn, David L.; Mayoral, Jaime L.; Gillingham, Kristen J.; Loeffler, Cynthia M.; Brayman, Kenneth L.; Kramer, Marie A.; Erice, Alejo; Balfour, Henry H.; Fletcher, Courtney V.; Morton Bolman, R.; Matas, Arthur J.; Payne, William D.; Sutherland, David E.R.; Najarian, John S.

In: Transplantation, Vol. 51, No. 1, 01.1991, p. 98-106.

Research output: Contribution to journalArticle

Dunn, DL, Mayoral, JL, Gillingham, KJ, Loeffler, CM, Brayman, KL, Kramer, MA, Erice, A, Balfour, HH, Fletcher, CV, Morton Bolman, R, Matas, AJ, Payne, WD, Sutherland, DER & Najarian, JS 1991, 'Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir', Transplantation, vol. 51, no. 1, pp. 98-106. https://doi.org/10.1097/00007890-199101000-00015
Dunn, David L. ; Mayoral, Jaime L. ; Gillingham, Kristen J. ; Loeffler, Cynthia M. ; Brayman, Kenneth L. ; Kramer, Marie A. ; Erice, Alejo ; Balfour, Henry H. ; Fletcher, Courtney V. ; Morton Bolman, R. ; Matas, Arthur J. ; Payne, William D. ; Sutherland, David E.R. ; Najarian, John S. / Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir. In: Transplantation. 1991 ; Vol. 51, No. 1. pp. 98-106.
@article{26f947c803844b0f987df567ec4ce021,
title = "Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir",
abstract = "The occurrence of cytomegalovirus infection after solid organ transplantation has been correlated with decreased patient and allograft survival. The disease has not been conquered for two major reasons: The length of time to establish the diagnosis of CMV has been excessive, and suitable, nontoxic antiviral agents have not been available for use. The purpose of this study was to examine the current incidence and impact of tissue-invasive cytomegalovirus (TI-CMV) disease that developed in 93 patients who underwent solid organ transplantation at University of Minnesota Hospitals (3/1/87 and 6/30/89) and who were treated with the antiviral agent ganciclovir ([9-(l, 3-dihydroxy-2-2-propoxymethyl)-guanine [DHPG]). During this same period of time 323 patients received kidney transplants and 71 received kidney-pancreas transplants. Three patient groups were defined: (1) no CMV; (2) CMV infection (cultural or serologic evidence of noninvasive CMV infection); and (3) evidence of TI-CMV disease based upon initial complaints of fever, malaise, dyspnea, or abdominal pain, leukopenia (WBC<3000/ml), and evidence of a positive CMV rapid antigen test, CMV culture, or the presence of characteristic CMV inclusion bodies upon examination of material obtained by means of bronchoscopy, upper-gastrointestinal endoscopy, colonoscopy, or liver or renal biopsy. Patients with solely fever, leukopenia, but without a rising CMV serum titer, or positive CMV urine or blood cultures were excluded from the study. A multivariate analysis revealed that rejection therapy, age >50 years, and receiving an organ from a seropositive donor were all significant variables that predisposed to TI-CMV. Analysis of patient and kidney allograft survival indicated that asymptomatic CMV infection had little current impact upon patient or allograft survival, while patients who developed TI-CMV exhibited higher rates of allograft loss and mortality, despite DHPG therapy. Comparison with historical group of patients indicated that TI-CMV DHPG-treated patients exhibited a trend toward improved allograft survival that may be relevant because the historical group of patients included patients with mild CMV in-fection. DHPG therapy was well tolerated and produced minimal toxicity, and excellent 30-day cure rates (89.2{\%}), although 21.2{\%} of patients required retreatment subsequently. We are currently conducting a trial to compare the ability of DHPG administered plus an anti-CMV immune globulin preparation with acyclovir to prevent posttransplant TI-CMV disease.",
author = "Dunn, {David L.} and Mayoral, {Jaime L.} and Gillingham, {Kristen J.} and Loeffler, {Cynthia M.} and Brayman, {Kenneth L.} and Kramer, {Marie A.} and Alejo Erice and Balfour, {Henry H.} and Fletcher, {Courtney V.} and {Morton Bolman}, R. and Matas, {Arthur J.} and Payne, {William D.} and Sutherland, {David E.R.} and Najarian, {John S.}",
year = "1991",
month = "1",
doi = "10.1097/00007890-199101000-00015",
language = "English (US)",
volume = "51",
pages = "98--106",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir

AU - Dunn, David L.

AU - Mayoral, Jaime L.

AU - Gillingham, Kristen J.

AU - Loeffler, Cynthia M.

AU - Brayman, Kenneth L.

AU - Kramer, Marie A.

AU - Erice, Alejo

AU - Balfour, Henry H.

AU - Fletcher, Courtney V.

AU - Morton Bolman, R.

AU - Matas, Arthur J.

AU - Payne, William D.

AU - Sutherland, David E.R.

AU - Najarian, John S.

PY - 1991/1

Y1 - 1991/1

N2 - The occurrence of cytomegalovirus infection after solid organ transplantation has been correlated with decreased patient and allograft survival. The disease has not been conquered for two major reasons: The length of time to establish the diagnosis of CMV has been excessive, and suitable, nontoxic antiviral agents have not been available for use. The purpose of this study was to examine the current incidence and impact of tissue-invasive cytomegalovirus (TI-CMV) disease that developed in 93 patients who underwent solid organ transplantation at University of Minnesota Hospitals (3/1/87 and 6/30/89) and who were treated with the antiviral agent ganciclovir ([9-(l, 3-dihydroxy-2-2-propoxymethyl)-guanine [DHPG]). During this same period of time 323 patients received kidney transplants and 71 received kidney-pancreas transplants. Three patient groups were defined: (1) no CMV; (2) CMV infection (cultural or serologic evidence of noninvasive CMV infection); and (3) evidence of TI-CMV disease based upon initial complaints of fever, malaise, dyspnea, or abdominal pain, leukopenia (WBC<3000/ml), and evidence of a positive CMV rapid antigen test, CMV culture, or the presence of characteristic CMV inclusion bodies upon examination of material obtained by means of bronchoscopy, upper-gastrointestinal endoscopy, colonoscopy, or liver or renal biopsy. Patients with solely fever, leukopenia, but without a rising CMV serum titer, or positive CMV urine or blood cultures were excluded from the study. A multivariate analysis revealed that rejection therapy, age >50 years, and receiving an organ from a seropositive donor were all significant variables that predisposed to TI-CMV. Analysis of patient and kidney allograft survival indicated that asymptomatic CMV infection had little current impact upon patient or allograft survival, while patients who developed TI-CMV exhibited higher rates of allograft loss and mortality, despite DHPG therapy. Comparison with historical group of patients indicated that TI-CMV DHPG-treated patients exhibited a trend toward improved allograft survival that may be relevant because the historical group of patients included patients with mild CMV in-fection. DHPG therapy was well tolerated and produced minimal toxicity, and excellent 30-day cure rates (89.2%), although 21.2% of patients required retreatment subsequently. We are currently conducting a trial to compare the ability of DHPG administered plus an anti-CMV immune globulin preparation with acyclovir to prevent posttransplant TI-CMV disease.

AB - The occurrence of cytomegalovirus infection after solid organ transplantation has been correlated with decreased patient and allograft survival. The disease has not been conquered for two major reasons: The length of time to establish the diagnosis of CMV has been excessive, and suitable, nontoxic antiviral agents have not been available for use. The purpose of this study was to examine the current incidence and impact of tissue-invasive cytomegalovirus (TI-CMV) disease that developed in 93 patients who underwent solid organ transplantation at University of Minnesota Hospitals (3/1/87 and 6/30/89) and who were treated with the antiviral agent ganciclovir ([9-(l, 3-dihydroxy-2-2-propoxymethyl)-guanine [DHPG]). During this same period of time 323 patients received kidney transplants and 71 received kidney-pancreas transplants. Three patient groups were defined: (1) no CMV; (2) CMV infection (cultural or serologic evidence of noninvasive CMV infection); and (3) evidence of TI-CMV disease based upon initial complaints of fever, malaise, dyspnea, or abdominal pain, leukopenia (WBC<3000/ml), and evidence of a positive CMV rapid antigen test, CMV culture, or the presence of characteristic CMV inclusion bodies upon examination of material obtained by means of bronchoscopy, upper-gastrointestinal endoscopy, colonoscopy, or liver or renal biopsy. Patients with solely fever, leukopenia, but without a rising CMV serum titer, or positive CMV urine or blood cultures were excluded from the study. A multivariate analysis revealed that rejection therapy, age >50 years, and receiving an organ from a seropositive donor were all significant variables that predisposed to TI-CMV. Analysis of patient and kidney allograft survival indicated that asymptomatic CMV infection had little current impact upon patient or allograft survival, while patients who developed TI-CMV exhibited higher rates of allograft loss and mortality, despite DHPG therapy. Comparison with historical group of patients indicated that TI-CMV DHPG-treated patients exhibited a trend toward improved allograft survival that may be relevant because the historical group of patients included patients with mild CMV in-fection. DHPG therapy was well tolerated and produced minimal toxicity, and excellent 30-day cure rates (89.2%), although 21.2% of patients required retreatment subsequently. We are currently conducting a trial to compare the ability of DHPG administered plus an anti-CMV immune globulin preparation with acyclovir to prevent posttransplant TI-CMV disease.

UR - http://www.scopus.com/inward/record.url?scp=0025980196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025980196&partnerID=8YFLogxK

U2 - 10.1097/00007890-199101000-00015

DO - 10.1097/00007890-199101000-00015

M3 - Article

C2 - 1846255

AN - SCOPUS:0025980196

VL - 51

SP - 98

EP - 106

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 1

ER -